Trial Outcomes & Findings for Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome (NCT NCT01331213)

NCT ID: NCT01331213

Last Updated: 2014-03-03

Results Overview

Colonic compliance is a measure of the "stiffness" of the colon, that is, what pressure was needed to reach half the maximum volume of the colon. After the barostat balloon catheter was inserted in the mid-descending or junction of the sigmoid and descending colon, the balloon was inflated. After an initial conditioning distension to 20 mm Hg, colonic compliance was measured by step-wise inflation with increments of 4 mm Hg. Colonic compliance was analyzed by a validated linear interpolation method. The pressure at half maximum volume serves as a summary of colonic compliance.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

18 participants

Primary outcome timeframe

baseline (1 hour before drug administration), post-treatment (1 hour after drug administration)

Results posted on

2014-03-03

Participant Flow

Participants were enrolled in the study between 4/2011 and 3/2012 at the Mayo Clinic in Rochester, Minnesota.

Participant milestones

Participant milestones
Measure
Pregabalin
Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
Placebo
Subjects randomized to this arm received a single dose of placebo orally.
Overall Study
STARTED
8
10
Overall Study
COMPLETED
8
10
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Pregabalin
n=8 Participants
Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
Placebo
n=10 Participants
Subjects randomized to this arm received a single dose of placebo orally.
Total
n=18 Participants
Total of all reporting groups
Sex: Female, Male
Male
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Region of Enrollment
United States
8 participants
n=99 Participants
10 participants
n=107 Participants
18 participants
n=206 Participants
Age, Continuous
44 years
STANDARD_DEVIATION 5.88 • n=99 Participants
44.1 years
STANDARD_DEVIATION 11.51 • n=107 Participants
44.06 years
STANDARD_DEVIATION 9.19 • n=206 Participants
Sex: Female, Male
Female
8 Participants
n=99 Participants
9 Participants
n=107 Participants
17 Participants
n=206 Participants

PRIMARY outcome

Timeframe: baseline (1 hour before drug administration), post-treatment (1 hour after drug administration)

Colonic compliance is a measure of the "stiffness" of the colon, that is, what pressure was needed to reach half the maximum volume of the colon. After the barostat balloon catheter was inserted in the mid-descending or junction of the sigmoid and descending colon, the balloon was inflated. After an initial conditioning distension to 20 mm Hg, colonic compliance was measured by step-wise inflation with increments of 4 mm Hg. Colonic compliance was analyzed by a validated linear interpolation method. The pressure at half maximum volume serves as a summary of colonic compliance.

Outcome measures

Outcome measures
Measure
Pregabalin
n=8 Participants
Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
Placebo
n=10 Participants
Subjects randomized to this arm received a single dose of placebo orally.
Colonic Compliance
Baseline
18.96 mm Hg
Standard Deviation 4.84
16.86 mm Hg
Standard Deviation 8.97
Colonic Compliance
Post-Treatment
15.99 mm Hg
Standard Deviation 6.4
15.75 mm Hg
Standard Deviation 7.89

PRIMARY outcome

Timeframe: The first 30 minutes postprandially, and preprandial (30 minutes)

The symmetric percent reduction in baseline colonic barostat balloon volume during the first 30 minutes postprandially (PP) corrected for the preprandial (30 min) tone, (symmetric percent change= 100\*log\_e\[fasting/PP\]). A positive symmetric percent change reflects a decrease in barostat balloon volume indicating a reduction in colonic tone. (The balloon was placed in the mid-descending or junction of the sigmoid and descending colon.)

Outcome measures

Outcome measures
Measure
Pregabalin
n=8 Participants
Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
Placebo
n=10 Participants
Subjects randomized to this arm received a single dose of placebo orally.
Postprandial Colonic Tone [Reported as the Symmetric Percent [Change} in Baseline Colonic Barostat Balloon Volume
-22.34 Symmetric percentage change
Standard Deviation 12.98
-24.45 Symmetric percentage change
Standard Deviation 12.3

PRIMARY outcome

Timeframe: approximately 60 minutes after drug administration

The sensory threshold for first perception of pain was measured by stepwise inflation of the balloon in increments of 4 mm Hg at 60 second intervals. The balloon was placed in the mid-descending or junction of the sigmoid and descending colon. During this assessment participants were asked to report when they had the first perception of pain. The investigator recorded the threshold pressure at which the participants reported this sensation.

Outcome measures

Outcome measures
Measure
Pregabalin
n=8 Participants
Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
Placebo
n=10 Participants
Subjects randomized to this arm received a single dose of placebo orally.
Sensory Threshold for Pain
36.0 mm Hg
Standard Deviation 17.59
38.0 mm Hg
Standard Deviation 21.02

PRIMARY outcome

Timeframe: Approximately 60 minutes after drug administration

The mm Hg distensions refer to the barostat balloon, which was placed in the mid-descending or junction of the sigmoid and descending colon. Pain sensation was measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes. For the pain VAS, 0 means no pain and 100 mm means extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain.

Outcome measures

Outcome measures
Measure
Pregabalin
n=8 Participants
Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
Placebo
n=10 Participants
Subjects randomized to this arm received a single dose of placebo orally.
Overall Sensory Ratings in Response to 16, 24, 30 and 36 mm Hg Distensions.
Sensation ratings of pain at 16 mm Hg distension
53.0 mm
Standard Deviation 11.83
52.3 mm
Standard Deviation 20.44
Overall Sensory Ratings in Response to 16, 24, 30 and 36 mm Hg Distensions.
Sensation ratings of pain at 24 mm Hg distension
57.43 mm
Standard Deviation 30.49
59.60 mm
Standard Deviation 26.71
Overall Sensory Ratings in Response to 16, 24, 30 and 36 mm Hg Distensions.
Sensation ratings of pain at 30 mm Hg distension
64.0 mm
Standard Deviation 26.12
60.3 mm
Standard Deviation 24.99
Overall Sensory Ratings in Response to 16, 24, 30 and 36 mm Hg Distensions.
Sensation ratings of pain at 36 mm Hg distension
59.0 mm
Standard Deviation 21.93
53.7 mm
Standard Deviation 33.4

SECONDARY outcome

Timeframe: Approximately 60 minutes after drug administration

Colonic tone is a measurement of the volume of the colon. Colonic tone was assessed by noting the changes in the balloon volume in the presence of a constant operating pressure in the balloon (in the barostat-manometric assembly placed in the colon.)

Outcome measures

Outcome measures
Measure
Pregabalin
n=8 Participants
Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
Placebo
n=10 Participants
Subjects randomized to this arm received a single dose of placebo orally.
Fasting Colonic Tone
120.4 mL
Standard Deviation 12.76
116.8 mL
Standard Deviation 24.75

SECONDARY outcome

Timeframe: Approximately 1 hour after meal

The postprandial motility index (MI)=log\_e\[number of contractions \* sum of amplitudes) + 1\] A normal fasting average motility index (MI) would be about 12. An increase in MI means an increase in the phasic contractions (in contrast to tone) which is measured as a change in volume of the barostatically-controlled balloon. (Therefore, an increase in MI means that the meal is moving more quickly through the colon.)

Outcome measures

Outcome measures
Measure
Pregabalin
n=8 Participants
Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
Placebo
n=10 Participants
Subjects randomized to this arm received a single dose of placebo orally.
Colonic Motility Index
Post-treatment, descending colon
13.69 log mm Hg
Standard Deviation 0.82
12.27 log mm Hg
Standard Deviation 2.09
Colonic Motility Index
Post-treatment, sigmoid colon
11.72 log mm Hg
Standard Deviation 1.58
10.21 log mm Hg
Standard Deviation 3.20

SECONDARY outcome

Timeframe: Approximately 60 minutes after drug administration

The sensory threshold for first perception of gas was measured by stepwise inflation of the balloon in increments of 4 mm Hg at 60 second intervals. The balloon was placed in the mid-descending or junction of the sigmoid and descending colon. During this assessment participants were asked to report when they had the first perception of gas. The investigator recorded the threshold pressure at which the participants reported this sensation.

Outcome measures

Outcome measures
Measure
Pregabalin
n=8 Participants
Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
Placebo
n=10 Participants
Subjects randomized to this arm received a single dose of placebo orally.
Post-treatment Sensory Threshold for Gas
24.0 mm Hg
Standard Deviation 12.65
19.2 mm Hg
Standard Deviation 13.31

Adverse Events

Pregabalin

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Michael Camilleri

Mayo Clinic

Phone: 507-266-2305

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place